14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CRAN vs CRANR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, CRAN (CRAN) is the stronger overall head-to-head candidate over CRANR (CRANR) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CRAN carries a Unified Composite Score of 62.8/100 (BUY) at $10.13 (N/M Forward P/E, N/A operating margin), whereas CRANR carries 46.4/100 (HOLD) at $0.16 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRAN vs CRANR. Trailing 12-month operating profitability (CRAN N/A vs CRANR N/A) and valuation multiples (CRAN N/M vs CRANR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRAN vs CRANR Key Questions & Quantitative Answers
As of Nov 20, 2026, CRAN (CRAN) is the stronger overall head-to-head candidate over CRANR (CRANR) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CRAN carries a Unified Composite Score of 62.8/100 (BUY) at $10.13 (N/M Forward P/E, N/A operating margin), whereas CRANR carries 46.4/100 (HOLD) at $0.16 (N/M Forward P/E, N/A operating margin). Technically, CRAN sits in a Markup phase (RSI 51.1, UNCLASSIFIED options structure) and CRANR sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure).
CRAN and CRANR split Growth & Scale metrics: CRAN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CRANR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CRAN generates N/A in USD-normalized revenue versus N/A for CRANR. In operating R&D and SG&A reinvestment, CRAN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRANR.
CRAN and CRANR trade at balanced relative valuation multiples. CRAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CRANR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRAN (N/A ROE) versus CRANR (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, CRAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 2% Vol realized risk). By comparison, CRANR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.44β · 324% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.